ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1575376
This article is part of the Research TopicCancer Therapy Related Organ ToxicitiesView all 9 articles
Clinical Features and Risk Factors of Immune-Mediated Liver Injury in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Provisionally accepted
- 1First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- 2Guangzhou Medical University, Guangzhou, Guangdong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study investigated the clinical features, risk factors, and recurrence of immune-mediated liver injury (IMLI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).A retrospective cohort of 274 NSCLC patients receiving ICIs was analyzed. Baseline inflammatory markers, including white blood cell count (WBC), albumin levels, and prognostic nutritional index (PNI), were assessed for their association with IMLI. Risk factors were identified using logistic regression, and recurrence outcomes were analyzed.IMLI incidence was 35.4%, with 15.5% of cases classified as grade 3-4. WBC ≤11.0×10⁹/L (P<0.001) and albumin ≥35 g/L (P<0.001) were independent predictors of IMLI. Among patients with IMLI, 28.9% experienced recurrence, with 17.9% classified as grade 3-4. Recurrence risk was not significantly higher than the initial onset (P=0.21).Low baseline inflammatory status predicts IMLI in NSCLC patients undergoing ICI therapy.Monitoring baseline inflammatory markers can guide risk stratification, and re-challenging ICIs in selected patients appears feasible without significantly increasing recurrence risk.
Keywords: immune checkpoint inhibitors, immune-mediated liver injury, Immune-related adverse events, Clinical features, Inflammatory biomarkers
Received: 12 Feb 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Yang, Zhuo, Li, Liu, Liu, Huang, Wu and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chao Zhuo, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.